ICML 2019 | ALPINE results: zanubrutinib vs. ibrutinib in CLL

Constantine Tam

The ALPINE study (NCT03734016) investigated zanubrutinib vs. ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL). Here, Constantine Tam, MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the results thus far from the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video